Abstract: To performing real-time bidirectional communication between robotic process automation (RPA) robots and a web application, a robot initiates execution of a primary workflow when a request is received from a web application. The robot then listens for one or more triggers from the web application to start execution of a secondary workflow, and executes the secondary workflow when the one or more triggers are detected. The robot also returns a result of the execution of the secondary workflow to the web application.

Abstract: Techniques for storing health data can include a multi-node data structure. A data node, a category node, and an institution node of a multi-node data structure can be generated in accordance with a configuration file. The data node can include health data and can be identified by a first unique data identifier and encrypted using a first cryptographic key. The category node can include the first unique data identifier and the first cryptographic key. The category node can be identified by a second unique data identifier and encrypted using a second cryptographic key. The institution node can include the second unique data identifier and the second cryptographic key. The institution node can be identified by a third unique data identifier and encrypted using a third cryptographic key. The data node, the category node, and the institution node can be shared with a service provider.

Abstract: Techniques for storing health data can include a multi-node data structure. A data node, a category node, and an institution node of a multi-node data structure can be generated in accordance with a configuration file. The data node can include health data and can be identified by a first unique data identifier and encrypted using a first cryptographic key. The category node can include the first unique data identifier and the first cryptographic key. The category node can be identified by a second unique data identifier and encrypted using a second cryptographic key. The institution node can include the second unique data identifier and the second cryptographic key. The institution node can be identified by a third unique data identifier and encrypted using a third cryptographic key. The data node, the category node, and the institution node can be shared with a service provider.

Abstract: Techniques for storing health data can include a multi-node data structure. A data node, a category node, and an institution node of a multi-node data structure can be generated in accordance with a configuration file. The data node can include health data and can be identified by a first unique data identifier and encrypted using a first cryptographic key. The category node can include the first unique data identifier and the first cryptographic key. The category node can be identified by a second unique data identifier and encrypted using a second cryptographic key. The institution node can include the second unique data identifier and the second cryptographic key. The institution node can be identified by a third unique data identifier and encrypted using a third cryptographic key. The data node, the category node, and the institution node can be shared with a service provider.

Abstract: A user device may share encrypted health data with an electronic health record (EHR) system associated with a health institution. A unique data identifier that identifies a portion of the health data and a cryptographic key may be shared with the EHR system. The encrypted health may be shared with a service provider and a unique data identifier. To access the health data, the EHR system may query the service provider with the unique data identifier.

Abstract: The present invention provides new procedure and intermediates for the preparation of Roxadustat (1) comprising: (A) reducing a compound of formula 3?, 3? or a mixture thereof: (3?), (3?) wherein Pg is H or a OH protecting group, Ri is alkyl, aryl, or arylalkyl; R2, R3, R4, and Rs each independently represents alkyl, arylalkyl or alkenyl, or R2 and R3 and/or R4 and Rs, taken together with the nitrogen atom to which they are bonded, each independently form a ring selected from: (I), wherein R6 is H or CI-6 alkyl; R7 is Ci to C6 alkyl and X— is an anion selected from the group consisting of halide, O—SO4—R7 wherein R7 is Ci to C6 alkyl, or O—SO2-Rs wherein Rs is phenyl, tolyl, methyl or trifluoromethyl; to form a compound of formula (2?) wherein Pg is H or an OH protecting group, Ri is alkyl, aryl, or arylalkyl; and removing the Ri group and where present removing the OH protecting group; or (B) reducing a compound of formula 4?, a compound of formula 4? or a mixture thereof: (4?), (4?) wherein Pg is H or an OH

Abstract: A user device may share encrypted health data with an electronic health record (EHR) system associated with a health institution. A unique data identifier that identifies a portion of the health data and a cryptographic key may be shared with the EHR system. The encrypted health may be shared with a service provider and a unique data identifier. To access the health data, the EHR system may query the service provider with the unique data identifier.

Abstract: A training operation for training a machine learning model may be initiated. At a predetermined checkpoint during the training operation, checkpoint information comprising a representation of the machine learning model in a partially trained state may be generated and stored in a non-volatile storage medium. The training operation for training the machine learning model may be continued after the predetermined checkpoint.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: Salts and crystalline forms of several salts of Varenicline, i.e., Varenicline sulfate: are provided, along with methods of preparing the solid states and processes for preparing Varenicline base from those Varenicline salts.

Abstract: Dry acid-concentrate compositions comprising citrate and their use in preparing dialysate compositions and in performing hemodialysis is disclosed.

Abstract: Crystalline forms of Varenicline Tosylate: are provided, along with processes for preparing those crystalline forms of Varenicline Tosylate, and processes for obtaining high purity Varenicline base using Varenicline Tosylate.

Abstract: Salts and crystalline forms of several salts of Varenicline, i.e., Varenicline sulfate, Varenicline mesylate, and Varenicline fumarate, methods of preparing the solid states of Varenicline sulfate, Varenicline mesylate, and Varenicline fumarate, and processes for preparing Varenicline base from those Varenicline salts are provided.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: Provided is a novel synthesis of quetiapine, and pharmaceutically acceptable salts thereof, in which an alkali metal halide or siliyl halide is included in the reaction mixture.

Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.

Abstract: The invention encompasses (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-2-azetidinone (Compound 2a) having an enantiomeric purity of at least about 97.5%. The invention also encompasses Compound 2a having a chemical purity of at least about 97%. The invention further encompasses processes for preparing Compound 2a from Compound 1 having the following formula: The invention also encompasses processes for preparing a compound having the following formula: from a compound having the following formula: wherein R is selected from the group consisting of: H or a hydroxyl protecting group. The invention also encompasses processes for preparing Compound 2a, preferably to form Compound 2a-Form 01.

Abstract: Crystalline forms of Varenicline Tosylate, processes for preparing those crystalline forms of Varenicline Tosylate, and processes for obtaining high purity Varenicline base using Varenicline Tosylate are provided.

Abstract: The invention provides an improved process for the preparation and purification of Varenicline and intermediates for the preparation of Varenicline.